OCULHealthcareSmall-Cap
OCULAR THERAPEUTIX, INC Insider Trading Activity
Every SEC Form 4 insider transaction reported for OCULAR THERAPEUTIX, INC (OCUL), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are OCUL insiders buying or selling?
OCULAR THERAPEUTIX, INC insiders reported 44 open-market buys ($25.9M) and 59 sells ($5.3M) across 103 Form 4 filings — a net buying position of $20.7M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jun 5, 2026)
Total Form 4 filings
103
SEC EDGAR
Insider filers
21
Insider buys (44)
$25.9M
Insider sells (59)
$5.3M
Insider sentiment
Net buyingNet insider flow of $20.7M in net buying.
Recent OCUL insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Nadia Waheed | Chief Medical Officer | Sale | 14.8K | $8.27 | $122.6K |
| May 28, 2026 | Pravin Dugel | Executive Chairman, President and CEO | Sale | 21.2K | $8.20 | $173.5K |
| May 28, 2026 | Peter Kaiser | Chief Development Officer | Sale | 3.0K | $8.20 | $24.3K |
| May 28, 2026 | Jeffrey S. Heier | Chief Scientific Officer | Sale | 3.0K | $8.20 | $24.7K |
| May 28, 2026 | Sanjay Nayak | Chief Strategy Officer | Sale | 1.9K | $8.20 | $15.2K |
| Feb 25, 2026 | Pravin Dugel | Executive Chairman, President and CEO | Sale | 20.1K | $8.28 | $166.1K |
| Feb 25, 2026 | Peter Kaiser | Chief Development Officer | Sale | 2.8K | $8.28 | $23.3K |
| Feb 25, 2026 | Jeffrey S. Heier | Chief Scientific Officer | Sale | 3.1K | $8.28 | $25.3K |
| Feb 25, 2026 | Sanjay Nayak | Chief Strategy Officer | Sale | 1.8K | $8.28 | $14.6K |
| Feb 24, 2026 | Nadia Waheed | Chief Medical Officer | Sale | 3.5K | $7.74 | $27.2K |
| Feb 24, 2026 | Richard L Lindstrom MD | Director | Purchase | 60.2K | $7.66 | $461.4K |
| Feb 18, 2026 | Donald Notman | Chief Operating Officer | Sale | 11.4K | $9.04 | $103.5K |
| Feb 18, 2026 | Sanjay Nayak | Chief Strategy Officer | Sale | 10.3K | $9.04 | $93.5K |
| Feb 18, 2026 | Pravin Dugel | Executive Chairman, President and CEO | Sale | 124.9K | $9.04 | $1.1M |
| Feb 18, 2026 | Nadia Waheed | Chief Medical Officer | Sale | 7.9K | $9.04 | $71.1K |
| Feb 5, 2026 | Donald Notman | Chief Operating Officer | Sale | 11.5K | $8.82 | $101.4K |
| Nov 26, 2025 | Sanjay Nayak | Chief Strategy Officer | Sale | 1.9K | $12.04 | $22.6K |
| Nov 26, 2025 | Pravin Dugel | Executive Chairman, President and CEO | Sale | 19.5K | $12.04 | $235.1K |
| Nov 26, 2025 | Peter Kaiser | Chief Development Officer | Sale | 3.0K | $12.02 | $36.1K |
| Nov 26, 2025 | Jeffrey S. Heier | Chief Scientific Officer | Sale | 3.5K | $12.04 | $41.8K |
| Nov 7, 2025 | Namrata Saroj | Chief Business Officer | Sale | 25.9K | $10.74 | $277.8K |
| Oct 10, 2025 | Todd Anderman | Chief Legal Officer | Sale | 11.1K | $12.34 | $137.4K |
| Oct 6, 2025 | Peter Kaiser | Chief Development Officer | Sale | 9.7K | $11.03 | $106.5K |
| Oct 6, 2025 | Jeffrey S. Heier | Chief Scientific Officer | Sale | 10.5K | $11.04 | $115.9K |
| Sep 4, 2025 | Donald Notman | Chief Financial Officer and Chief Operating Officer. Exhibit Index Exhibit 24 - Power of Attorney | Sale | 1.1K | $12.43 | $13.3K |
Showing the 25 most recent of 103 Form 4 filings for OCULAR THERAPEUTIX, INC.
Most active OCUL insiders
- SUMMER ROAD LLC17 filings
- Jeffrey S. Heier10 filings
- Pravin Dugel10 filings
- Sanjay Nayak10 filings
- Donald Notman9 filings
Ask anything about OCUL insider activity
Use Trabud's AI agent to query OCULAR THERAPEUTIX, INC's Form 4 history in plain English — "Show me OCUL CEO purchases this year" or compare it against any other ticker.
Open the AI agentOCUL insider trading FAQ
Are OCULAR THERAPEUTIX, INC insiders buying or selling?
Across 103 SEC Form 4 filings, OCULAR THERAPEUTIX, INC (OCUL) insiders reported 44 open-market purchases totaling $25.9M and 59 sales totaling $5.3M. That is a net buying position of $20.7M.
How many insiders trade OCUL stock?
21 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for OCULAR THERAPEUTIX, INC. The most recent filing was accepted on Jun 5, 2026.
Where does Trabud get OCUL insider trading data?
All OCUL insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.